Biora Bioex Ab

Institut Straumann Ag

Petter Lyngstadaas

Stina Gestrelius

Ivan Slaby

Tomas Hammargren

Christer Andersson

Lars Hammarstr&ouml;m

Lars Hammarström

The present invention relates to the use of a preparation of an active enamel matrix substance, such as an amelogenin, for the manufacture of a pharmaceutical composition for modulating an immune response. The composition can be used in preventing and/or treating a condition or disease in a mammal that is characterised by said mammal presenting an imbalance in its native immune response to an internal and/or external stimuli, i.e. wherein at least a part of said mammal's immune system is stimulated non-discriminatingly, reacts hypersensitively to said immunogen, or fails to react to said stimuli. Said condition can typically either be systemic or local, such as a systemic and/or post-traumatic whole-body inflammation or an autoimmune disease.

Enamel matrix protein composition for treatment of systemic inflammatory response

Enamel matrix protein composition for treatment of systemic inflammatory response syndrome

Active enamel substances may be used for the preparation of a pharmaceutical or cosmetic composition for healing of a wound, improving healing of a wound, soft tissue regeneration or repair, or for preventing or treating infection or inflammation.

Matrix protein composition for treating inflammation

Matrix protein compositions for treating infection

Matrix protein compositions for wound healing

Growing community of inventors

Nesoddtangen, Norway

Petter Lyngstadaas